Public release date: 17-Sep-2013 [ | E-mail | Share ] Contact: David McKeon dmckeon@nyscf.org 212-365-7440 New York Stem Cell Foundation New York, NY (September 17, 2013) The New York Genome Center (NYGC) announced today that The New York Stem Cell Foundation (NYSCF) has become an Associate Member, joining NYGC's growing consortium of 16 research and clinical institutions, all working together in new ways to utilize genomic data for better detection, treatment, and prevention of disease. "Biologists at the NYSCF working with the genomic scientists at NYGC will help address some of the critical roadblocks in stem cell research," said Dr. Robert B. Darnell, President and Scientific Director of NYGC. "Modern genomics has the potential to provide vital missing information to help us learn how to harness stem cells for use in clinical medicine. We've developed techniques and ideas here at NYGC that will greatly synergize with the beautiful and pioneering work ongoing at the NYSCF." Stem cell biology and genomic analysis are both critical to the advancement of precision medicine. The collaboration between the Genome Center and NYSCF will merge cutting-edge capabilities in human biology with genomic research, creating an optimal environment for translating research into a better standard of … Continue reading →

TORONTO, ONTARIO--(Marketwired - Sep 17, 2013) - Stem Cell Therapeutics Corp. (TSX VENTURE:SSS)(SCTPF), a biopharmaceutical company developing cancer stem cell-related therapeutics, today announces that it has adopted a shareholder rights plan (the "Plan") effective September 16, 2013. The Company will be seeking shareholder approval of the Plan at its next annual general and special meeting of shareholders. The Plan is designed to ensure the fair and equal treatment of shareholders in connection with any take-over bid for outstanding common shares of the Company. The Plan is not intended to prevent or deter take-over bids that offer fair treatment and value to shareholders, but is designed to encourage offers that represent fair value to all shareholders. The Plan seeks to provide shareholders with adequate time to properly assess a take-over bid without undue pressure. It also provides the Board of Directors with adequate time to fully assess an unsolicited take-over bid, to allow competing bids to emerge, and, if applicable, to explore other alternatives to the take-over bid to maximize shareholder value. Under the terms of the Plan, one right will be issued by the Company for each outstanding Stem Cell Therapeutics ("SCT") common share at the close of business on … Continue reading →

Treatment options for epilepsy Jehuda Sepkuty, M.D., Medical Director of the Epilepsy Center and Clinical Neurophysiology Program at the Swedish Neuroscience Institute, talks about diagnos... By: swedishseattle … Continue reading →

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Sunovion Pharmaceuticals Inc. (Sunovion) today announced that two completed Phase 3 trials of eslicarbazepine acetate (ESL) as a monotherapy treatment (Studies 093-045 and 093-046) met their primary endpoint. ESL was well-tolerated and demonstrated seizure control rates superior to historical controls in adult patients with partial-onset seizures with or without secondary generalization who were not well-controlled by current antiepileptic drugs (AEDs). ESL is an investigational AED currently under review by the U.S. Food and Drug Administration (FDA) for use as a once-daily adjunctive therapy in the treatment of partial-onset seizures in patients 18 years and older with epilepsy. The efficacy and safety of ESL as an adjunctive or monotherapy treatment for partial-onset seizures in adults living with epilepsy has not yet been established. We are pleased to achieve this important milestone in monotherapy, which builds upon our existing data in adjunctive therapy for patients suffering from partial-onset seizures, said Fred Grossman, D.O., FAPA, Senior Vice President, Clinical Development and Medical Affairs at Sunovion. Pending the outcome of FDA review of the current New Drug Application (NDA) resubmission for eslicarbazepine acetate as an adjunctive treatment, Sunovion plans to submit these data as part of a supplemental NDA in support … Continue reading →

SAN DIEGO--(BUSINESS WIRE)-- As the number of children diagnosed with autism has skyrocketed, thousands of families face daily challenges with unpredictable outbursts, aggressive behaviors, compulsions, and withdrawal from contact. In the new book Spectacular Bond: Reaching the Child with Autism, two doctors from Columbia University and a parent of a child with autism present a life-changing autism treatment program that leads to major improvements in behavior, communication, and social interaction. The program Spectacular Bond takes aspects of the parent-child relationship that typically run on auto-pilot and brings these intricacies into consciousness. Conscious control over these subtle and typically hidden aspects of the parent-child relationship enables parents to confidently handle the range of challenging behaviors they encounter. The book details a six-component plan that, within weeks, leads to The end result is a transformation in the life of the child, the parent, and all members of the family. Spectacular Bond is the only autism behavior program that combines the latest research in neuroscience, linguistics, and the psychology of parent-child interaction. In a field where meaningful progress is thought to take years to achieve, this book shakes conventional wisdom. The program diverges from current mainstream treatment models. Most parents of children with … Continue reading →

Featured Article Academic Journal Main Category: Sleep / Sleep Disorders / Insomnia Also Included In: Cardiovascular / Cardiology Article Date: 16 Sep 2013 - 8:00 PDT Current ratings for: 'Beauty rest' effect of CPAP sleep apnea treatment 5 (2 votes) 5 (1 votes) Getting a good night's rest can improve our health in many ways. And now, a new study published in the Journal of Clinical Sleep Medicine is the first of its kind to analyze how patients appear more alert, youthful and attractive after undergoing sleep apnea treatment for 2 months. The treatment, called continuous positive airway pressure (CPAP) therapy, can stop snoring, improve alertness and reduce blood pressure by keeping the airway open through a stream of air delivered by a mask that is worn during sleep. It helps patients with obstructive sleep apnea (OSA), which researchers say is a sleep illness that is linked to an increased risk of high blood pressure, heart disease, diabetes, depression and stroke. However, for some patients, sticking with the CPAP treatment can be a challenge because they must wear the breathing mask all through the night. After anecdotal stories about how patients appeared to look better after consistently following CPAP treatment, … Continue reading →